EXACT SCIENCES

# CARE ACROSS THE CANCER CONTINUUM




Exact Sciences is changing the way we think about detecting and treating cancer. As a leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.

Exact Sciences' portfolio of products focuses on colorectal, breast, prostate, lung, and liver cancers. In research and development, we are also looking at multi-cancer early detection (MCED), a new kind of blood test that is designed to find cancer at earlier stages, when it's most treatable.

From earlier cancer detection to treatment guidance and monitoring, we aim to offer a comprehensive suite of tests to enable the delivery of personalized care across the cancer continuum.

## CANCER IS DETECTED TOO LATE

Cancer is a thief. It robs us of our family members, of our comfort, of once-in-a-lifetime opportunities. But most of all, cancer is a stealer of time. But what if we could steal time back? What if we could transform the suffering caused by cancer into the joy of living a full and thriving life? **We believe we can help make this world a reality.**

**1 in 5**
diagnosed with cancer in their lifetime[1]

**1 in 6**
deaths worldwide attributed to cancer[1]

**10M**
total annual cancer deaths[1]

## CHANGING LIVES, TOGETHER

Exact Sciences is uniquely positioned to impact patients across the cancer contiuum through **our global team, capabilities and infrastructure, and dedication to taking on the impossible.** We are continuously innovating, combining scientific rigor with an open-minded approach to deliver the next big thing.

Nearly
**4M**
people tested in 2021[2]

Over
**6,500**
global employees[2]

**10**
research and development centers and labs around the globe[2]
(3 in WI, 2 in CA, 1 in AZ, 1 in MD, 1 in MA, 1 in Germany, 1 in UK)

Exact Sciences understands the need to invest in our backyard, as well as the global community, **to improve health, defeat cancer, and leave a better planet for the next generation.** We support United Way's campaigns to improve lives around the world through education, health, and financial stability. We also collaborate with the Urban League of Greater Madison, where we are headquartered, to offer free job skills training to community members.

# PRODUCT PORTFOLIO

Note: tests are available in the United States. Availability outside of the U.S. differs by country.

## Cologuard®

Cologuard is a stool DNA-based test for colorectal cancer screening for average-risk patients 45 and older[3]. It is effective, non-invasive, and FDA approved. Cologuard is a convenient option that patients can use in the privacy of their own homes, with no special prep, time off or changes in diet or medication necessary. Cologuard finds 92% of colon cancers, even in early stages[3]. Cologuard is not for high-risk individuals. In 2019, the FDA approved Cologuard for use in eligible average-risk adults, starting at age 45, expanding on its previous indication for ages 50 and older. In 2021, the US Preventive Services Task Force (USPSTF) lowered the recommended age for average-risk adults to begin screening for colorectal cancer to age 45, instead of 50[6].

## Oncoguard® Liver

The Oncoguard Liver solution was designed with the hope of bringing better outcomes to more people at risk of Hepatocellular Carcinoma (HCC), the most common form of liver cancer. The sophisticated, yet simple, blood test is for adults with liver cirrhosis and/or chronic hepatitis B (HBV) who are at risk for HCC. Designed for high performance to enable early-stage detection[4], the test is complemented by a Patient Engagement Program to help empower patients to proactively protect their health and follow through with routine testing. Together, the Oncoguard® Liver solution offers a streamlined approach to liver cancer detection.

## Oncotype DX®

Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smarter at every stage, our Oncotype DX diagnostic tests and services portfolio delivers clinically relevant genomic intelligence specific to the individual biology of a patient's tumor. This additional genomic insight helps physicians optimize treatment decisions for breast, colon, and prostate cancers.

## Oncomap™

The Oncomap test delivers rapid, comprehensive tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. The test identifies actionable genomic alterations within seven days[2,†] and with small tissue sample sizes[2], helping guide timely discussions and decisions, while helping physicians to understand a patient's tumor profile to recommend targeted therapies or clinical trials.

## Oncomap™ ExTra

The Oncomap ExTra test detects damage in tumor genes and provides an extensive biological picture of certain refractory, rare, or aggressive cancers. With an extensive panel of approximately 20,000 genes and 169 introns, the Oncomap ExTra test is a comprehensive panel including whole-exome (DNA) and whole-transcriptome (RNA) panels. It provides physicians, academic medical centers, select community practices, and biopharma researchers with vital interpreted information to understand changes to a patient's tumor genomic profile to recommend therapeutic treatment plans.[5]

# OUR PIPELINE

Building on the success of the Cologuard and Oncotype® tests, the company is investing in its product pipeline across the cancer continuum. A multi-cancer early detection (MCED) blood test in development has the potential to make routine screening for multiple types of cancer a reality. We are also developing solutions for minimal residual disease (MRD) testing that may help discover cancer recurrence earlier. We are collaborating with Mayo Clinic, Johns Hopkins University, and The Translational Genomics Research Institute (an affiliate of City of Hope), to develop a pipeline of new cancer detection tests. Using proprietary DNA chemistry and the flexible automated laboratory platform, the goal is to develop blood-based cancer tests that empower the detection of cancers in their earliest, most treatable stages.

† Turnaround time is based on qualified sample receipt.

**Sources**


1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin*. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Internal Data on File. Exact Sciences Corporation. Madison, WI.
3. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*. 2014;370(14):1287-1297. doi:10.1056/NEJMoa1311194
4. Chalasani NP, Porter K, Bhattacharya A, Book AJ, Neis BM, Xiong KM, Ramasubramanian TS, Edwards V DK, Chen I, Johnson S, Roberts LR, Kisiel JB, Reddy KR, Singal AG, Olson MC, Bruinsma JJ, Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma, *J. Clinical Gastroenterology and Hepatology* (2021), doi: https:// doi.org/10.1016/j.cgh.2021.08.010
5. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. *Sci Transl Med*. 2015;7(283):283ra53. doi:10.1126/scitranslmed.aaa7161
6. Davidson KW, Barry MJ, Mangione CM, et al. Screening for colorectal cancer - US Preventive Services Task Force recommendation statement. *JAMA*. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238


**For more information on Exact Sciences, please visit the company's website www.exactsciences.com and follow Exact Sciences on Twitter, Facebook or LinkedIn.**

EXACT SCIENCES